Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05113368 · ClinicalTrials.gov registry record · Phase 2
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
A Phase 2 study of Ovarian Cancer and Serous Ovarian Cancer, sponsored by Sarah K. Lynam MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT05113368: Recruiting Phase 2 study of Ovarian Cancer and Serous Ovarian Cancer, sponsored by Sarah K. Lynam MD.
NCT05113368 is a Phase 2 study of Ovarian Cancer and Serous Ovarian Cancer that is actively recruiting participants, run by Sarah K. Lynam MD. The registered enrollment target is 31 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05113368, a Phase 2 study of Ovarian Cancer and Serous Ovarian Cancer, is actively recruiting participants, sponsored by Sarah K. Lynam MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian cancer.
Primary Outcome
To assess the efficacy of this regimen in term of overall objective response rate (complete response rate) at 12 weeks as assessed by the Investigator, per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1). The number of participants that reach a complete response (CR) defined as normalization of tumor markers, tumor nodes \<10 mm.
Conditions Studied
Interventions
- DRUG Regorafenib
- DRUG Fulvestrant
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2022-06-28 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
What NCT05113368 shows while recruiting
NCT05113368 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Regorafenib is the first listed.
NCT05113368 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05113368 about?
NCT05113368 is a clinical study titled "Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer". To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian cancer.
What is the current status of trial NCT05113368?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2022-06-28. Estimated completion is 2027-02.
What conditions does trial NCT05113368 study?
This clinical trial studies the following conditions: Ovarian Cancer, Serous Ovarian Cancer.
What interventions are being tested in trial NCT05113368?
The interventions under investigation include: Regorafenib (DRUG), Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT05113368?
This trial is sponsored by Sarah K. Lynam MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05113368 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05113368's enrollment target sits among peer trials
31 251st of 322 higher than 72 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI